975 related articles for article (PubMed ID: 19167259)
21. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
22. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
23. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
24. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Tse W
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
[TBL] [Abstract][Full Text] [Related]
25. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
Elmer LW
Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.
Zhou CQ; Zhang JW; Wang M; Peng GG
J Clin Neurosci; 2014 Jul; 21(7):1094-101. PubMed ID: 24786715
[TBL] [Abstract][Full Text] [Related]
30. Selegiline slows the progression of the symptoms of Parkinson disease.
Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
[TBL] [Abstract][Full Text] [Related]
31. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
[TBL] [Abstract][Full Text] [Related]
32. Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of clinical efficacy?
Rinne JO; Ulmanen I; Lee MS
Am J Pharmacogenomics; 2003; 3(1):11-5. PubMed ID: 12562212
[TBL] [Abstract][Full Text] [Related]
33. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
34. Entacapone in the treatment of Parkinson's disease.
Schrag A
Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
[TBL] [Abstract][Full Text] [Related]
35. Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
Jann MW
Am J Manag Care; 2011 Oct; 17 Suppl 12():S315-21. PubMed ID: 22087552
[TBL] [Abstract][Full Text] [Related]
36. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
[TBL] [Abstract][Full Text] [Related]
37. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
38. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
39. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
[TBL] [Abstract][Full Text] [Related]
40. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
